Extracellular Vesicles Derived Human-miRNAs Modulate the Immune System in Type 1 Diabetes

Tesovnik, Tine; Kovač, Jernej; Pohar, Katka; Hudoklin, Samo; Dovč, Klemen; Bratina, Nataša; Podkrajšek, Katarina Trebušak; Debeljak, Maruša; Veranič, Peter; Bosi, Emanuele; Piemonti, Lorenzo; Ihan, Alojz; Battelino, Tadej

doi:10.3389/fcell.2020.00202

Cited by 33 publications

(35 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…miR-129-5p was significantly overexpressed in Langerhans islets transplantation patients [80]. The expression of miR-129 was significantly downregulated in CRC tissue specimens compared with the paired normal control samples [81].…”

Section: Microrna Biomarkersmentioning

confidence: 93%

MicroRNA, Diabetes Mellitus and Colorectal Cancer

Wang

2020

Biomedicines

View full text Add to dashboard Cite

Diabetes mellitus (DM) is an endocrinological disorder that is due to either the pancreas not producing enough insulin, or the body does not respond appropriately to insulin. There are many complications of DM such as retinopathy, nephropathy, and peripheral neuropathy. In addition to these complications, DM was reported to be associated with different cancers. In this review, we discuss the association between DM and colorectal cancer (CRC). CRC is the third most commonly diagnosed cancer worldwide that mostly affects older people, however, its incidence and mortality are rising among young people. We discuss the relationship between DM and CRC based on their common microRNA (miRNA) biomarkers. miRNAs are non-coding RNAs playing important functions in cell differentiation, development, regulation of cell cycle, and apoptosis. miRNAs can inhibit cell proliferation and induce apoptosis in CRC cells. miRNAs also can improve glucose tolerance and insulin sensitivity. Therefore, investigating the common miRNA biomarkers of both DM and CRC can shed a light on how these two diseases are correlated and more understanding of the link between these two diseases can help the prevention of both DM and CRC.

show abstract

Section: Microrna Biomarkersmentioning

confidence: 93%

MicroRNA, Diabetes Mellitus and Colorectal Cancer

Wang

2020

Biomedicines

View full text Add to dashboard Cite

show abstract

“…Further studies have shown that co-incubation of diabetic EVs with monocytes could reduce the expression of genes related to apoptosis and oxidative stress in monocytes ( 36 , 58 ). It also increased the expression of many proinflammatory cytokines ( 58 – 60 ). These findings suggest that EVs in diabetic patients promote monocyte survival and promote monocyte inflammatory activation.…”

Section: Effects Of Exosomes In Diabetes Mellitusmentioning

confidence: 97%

Exosomes: Biomarkers and Therapeutic Targets of Diabetic Vascular Complications

Chen

Wang

et al. 2021

Front. Endocrinol.

View full text Add to dashboard Cite

Diabetic vascular complications (DVC) including macrovascular and microvascular lesions, have a significant impact on public health, and lead to increased patient mortality. Disordered intercellular cascades play a vital role in diabetic systemic vasculopathy. Exosomes participate in the abnormal signal transduction of local vascular cells and mediate the transmission of metabolic disorder signal molecules in distant organs and cells through the blood circulation. They can store different signaling molecules in the membrane structure and release them into the blood, urine, and tears. In recent years, the carrier value and therapeutic effect of exosomes derived from stem cells have garnered attention. Exosomes are not only a promising biomarker but also a potential target and tool for the treatment of DVC. This review explored changes in the production process of exosomes in the diabetic microenvironment and exosomes’ early warning role in DVC from different systems and their pathological processes. On the basis of these findings, we discussed the future direction of exosomes in the treatment of DVC, and the current limitations of exosomes in DVC research.

show abstract

“…Regardless of the approach, WGS or targeted, there are some properties of the human genome being uncovered, that neither could be detected without complex technical modifications or a special type of human genome analysis. The role of epigenetics and non-coding RNAs on the expression of genes is just starting to be discovered (Tesovnik et al, 2020). The role of topologically associated domains and interchromosomal interactions and the influence of the 3D structure of the genome in the expression of genes and potential cause of the disease are still not fully understood (Maass et al, 2018(Maass et al, , 2019.…”

Section: Technical Feasibilitymentioning

confidence: 99%

Next-Generation Sequencing in Newborn Screening: A Review of Current State

et al. 2021

Self Cite

View full text Add to dashboard Cite

Newborn screening was first introduced at the beginning of the 1960s with the successful implementation of the first phenylketonuria screening programs. Early expansion of the included disorders was slow because each additional disorder screened required a separate test. Subsequently, the technological advancements of biochemical methodology enabled the scaling-up of newborn screening, most notably with the implementation of tandem mass spectrometry. In recent years, we have witnessed a remarkable progression of high-throughput sequencing technologies, which has resulted in a continuous decrease of both cost and time required for genetic analysis. This has enabled more widespread use of the massive multiparallel sequencing. Genomic sequencing is now frequently used in clinical applications, and its implementation in newborn screening has been intensively advocated. The expansion of newborn screening has raised many clinical, ethical, legal, psychological, sociological, and technological concerns over time. This review provides an overview of the current state of next-generation sequencing regarding newborn screening including current recommendations and potential challenges for the use of such technologies in newborn screening.

show abstract

Extracellular Vesicles Derived Human-miRNAs Modulate the Immune System in Type 1 Diabetes

Cited by 33 publications

References 86 publications

MicroRNA, Diabetes Mellitus and Colorectal Cancer

MicroRNA, Diabetes Mellitus and Colorectal Cancer

Exosomes: Biomarkers and Therapeutic Targets of Diabetic Vascular Complications

Next-Generation Sequencing in Newborn Screening: A Review of Current State

Contact Info

Product

Resources

About